MSL Immunology North of Portugal

At Johnson & Johnson,? we believe health is everything. Our strength in healthcare innovation empowers us to build a? world where complex diseases are prevented, treated, and cured,? where treatments are smarter and less invasive, and? solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at https://www.jnj.com/.

MAIN ACTIVITIES

• To maximize company product value through high scientific quality communication with Leading Specialists on a peer-to-peer basis. Accordingly, to strategic lines of Medical Affairs Plan, the MSL is jointly responsible for achieving short-term and long-term company goals at local level.
• To be a therapeutic area scientific expert, responsible for discussing our products, patients’ treatment trends and studies in the therapeutic areas in which we are involved, on a peer-to-peer basis with a defined audience of Leading Specialists (Physicians, Pharmacists, Hospital Managers, Board Members of Scientific Societies, and other stakeholders) and to be considered an internal and external trusted scientific counterparts

TASKS

• To keep abreast of medical and scientific knowledge
• Continuous update on products, patient’s treatment trends, clinical activities and studies conducted within the therapeutic area in their region.

• Development and maintenance of a contact network with Leading Specialists
• Understand their needs, key value drivers, practical treatment patterns and scientific activities within therapeutic area
• Communicate value of company products, incl. clinical questionnaire discussions
• Through scientific interactions, communicate medical benefits of products and contribute to foster innovative approaches
• Represent the company within professional associations in the therapeutic area in cooperation with Medical Affairs/ Medical Education and other positions in the Medical Affairs Department
• Proactive and reactive communication of medical scientific data according to following criteria
• Proactive Scientific Communication to Leading Specialists must be consistent with the last approved Summary of Product Characteristics regarding the safe and effective use of approved products in approved indications. Content of Scientific Communication should be highly scientific, accurate, fair and objective, based on an up-to-date evaluation of all relevant evidence and reflect that evidence clearly, using neither marketing claims nor brand name, for individual or groups of physicians (group calls)
• In some very specific circumstances, the MSL can interact proactively with non-Leading

Specialists. The program should be clearly defined in the MSL Country Activity Plan, providing the rational, the objective, content, timelines and selection criteria of the HCPs to be involved

• Description of R&D programs and discussing regulatory developments with no promotional intent are also part of Scientific Communication.
• Reactive Communication of medical scientific data can be provided upon request to any Health Care Professional, within the approved label or off-label. The request should come either directly from the HCP or via the Medical Information department. MSLs are required to document all off-label information requests they receive from Leading Specialists and other HCPs that they may interact with.
• Organization and participation in Medical Education activities, at local &/regional level
• Identify/support/educate speakers
• Build Medical Education programs with scientific third party
• Collaborate with Medical Education manager in National Medical education activities
• Provide scientific material under request. MSLs may initiate discussion with potential speakers, discussing documents/ slides which may be of help for future presentations.
• Organization and participation in Advisory Boards in cooperation with Medical Affairs/Medical Education/other positions in the Medical Affairs Department.
• Market Access Discussions

MSLs can present highly scientific, accurate, fair and objective data to Payors (Hospital Formulary Committees, Health Insurers, Health Technology Assessment Committees, etc) to provide them with objective information about Company products.

• Pre- Approval Activities

MSLs can engage in interactions with Payors to raise awareness so that payors can plan and budget so that patients can receive the product when it becomes available. MSLs can organize Speakers training to prepare speakers for delivering presentations to other HCP when the Marketing Authorization is granted.

• Provision of scientific support to company Sales Representatives and other company representatives
• Provide medical and product training and scientific support to Sales Representatives in coordination with Training/Medical Affairs Department as appropriate
• Act as a reference point to Sales Representatives for any scientific query, in collaboration with Medical Information as appropriate.
• Local implementation of Medical Affairs Plan in their areas
• Support the set up and follow up of local company sponsored studies, registries and other non-interventional Medical Affairs studies
• Propose investigators and sites for interventional and non-interventional Medical Affairs studies.
• Participate in investigator meetings preparation, recruitment follow-up and study result presentation.
• Receive investigator proposals for IIS and ensure they are discussed within the Medical Affairs department for decision.
• Participate in NPP programmes giving scientific support and guidance to physicians
• Through scientific interactions, gain valuable insight into treatment patterns and scientific activities in the therapeutic area and provide input and a strategic view to the company Medical Affairs Plan / business decision-making.
• Observes and promotes all regulatory requirements as defined in applicable regulations, rules and procedures established by the Company, including but not limited to Health Care Business Integrity and Pharmacovigilance
• Follow principles, procedures and training included in SAFE Fleet program.
• GCO collaboration: Support GCO studies when needed through the identification of potential sites and facilitating a direct contact with leading specialists
• Report all suspected adverse reactions, serious or non serious within a maximum of 24 hours after being aware of it and communicat e it to the Pharmacovigilance Department.